SF3B1

SOPHiA GENETICS Launches New Solution to Advance Chronic Lymphocytic Leukemia Care, in Collaboration with IDIBAPS

Retrieved on: 
Thursday, June 9, 2022
Institute, Platform, Chronic lymphocytic leukemia, Sophia, Technology, Research, Generalitat, U.S. Securities and Exchange Commission, Blood, SF3B1, Forward-looking statement, Partnership, Solution, Trisomy, Faculty, Acute myeloid leukemia, Lymphoma, BTK, CLL, Biomedical Research, Noise, DDM, CNV, Guideline, Algorithm, SNV calling from NGS data, University, Health, Patient, DNA, PLCG2, Sophia Genetics, University of Barcelona, Software as a service, Leukemia, NGS, GENETICS, LinkedIn, Disease, Environment, Catalan, ATM, TP53, NOTCH1, Workflow, BCL2, 2015–16 Catalan government formation, Twitter, Instagram, Medical device, Pharmaceutical industry, Genetics, Hematology, Medicine

SOPHiA GENETICS has already facilitated the analysis of one million genomic profiles through the SOPHiA DDM Platform, including a significant amount of onco-hematological-related diseases such as acute myeloid leukemia and lymphomas.

Key Points: 
  • SOPHiA GENETICS has already facilitated the analysis of one million genomic profiles through the SOPHiA DDM Platform, including a significant amount of onco-hematological-related diseases such as acute myeloid leukemia and lymphomas.
  • The new CLL solution allows for progress of Chronic Lymphocytic Leukemia research using genomic analysis.
  • "We are proud to work together with some of the most renowned experts in the field of Chronic Lymphocytic Leukemia research around the world.
  • Forward-looking statements are based on SOPHiA GENETICS' management's beliefs and assumptions and on information currently available to its management.

Exo Therapeutics Appoints Antonio Gualberto as President of Research & Development and Chief Medical Officer

Retrieved on: 
Tuesday, January 18, 2022
Health, Other Science, Research, Pharmaceutical, Science, Biotechnology, Merck Serono, Exo, Patient, Pleasure, Technology, Case Western Reserve University, Inflammation, Brentuximab vedotin, Board of directors, CMO, Protein, CEO, Development, Takeda, University of North Carolina at Greensboro, Research and development, Â, Therapy, Drug development, Lawrence Berkeley National Laboratory, Biomedicine, Doctor of Philosophy, Chapel Hill, University of Seville, University, SF3B1, Pharmaceutical industry, Pfizer, MD

Exo Therapeutics, Inc. , a company pioneering the discovery and development of small molecules that can reprogram protein targets through binding to exosites, today announced the appointment of Antonio Gualberto, MD, PhD, as President of Research & Development and Chief Medical Officer.

Key Points: 
  • Exo Therapeutics, Inc. , a company pioneering the discovery and development of small molecules that can reprogram protein targets through binding to exosites, today announced the appointment of Antonio Gualberto, MD, PhD, as President of Research & Development and Chief Medical Officer.
  • It is my pleasure to welcome Antonio to Exo and work with him as we continue to progress our programs, said Michael Bruce, PhD, CEO of Exo Therapeutics.
  • Im excited to lead the discovery and development of these novel agents, said Dr. Gualberto.
  • Exo Therapeutics is a small molecule drug discovery and development company with a pioneering technology to address intractable pharmaceutical targets.

Data Published in Ocular Oncology and Pathology Demonstrates Highly Accurate Performance of DecisionDx®-UMSeq for Patients with Uveal Melanoma

Retrieved on: 
Wednesday, January 12, 2022
Oncology, Health, Genetics, Research, Science, Optical, Biotechnology, Atopic dermatitis, Securities Exchange Act of 1934, Journal of the National Comprehensive Cancer Network, LinkedIn, SEC, DecisionDx-UM, American Joint Committee on Cancer, UM, PLCB4, List of life sciences, J. William Harbour, Melanoma, RNA, Biopsy, COVID-19, GNA11, Adult, Collection, Instagram, Disease management, Nasdaq, University of Texas Southwestern Medical Center, Company, PRAME, EIF1AX, National Comprehensive Cancer Network, Patient, Pathology, Metastasis, Indel, BAP1, Uveal melanoma, Gene, Health, DNA, Cancer, PPA, GNAQ, AJCC, Neoplasm, Professor, Personal Data Privacy and Security Act of 2009, CYSLTR2, Securities Act of 1933, SNV calling from NGS data, NGS, FNAB, Wilms' tumor, Exon, Department, Tissue, Risk, Twitter, GEP, Physician, SF3B1, Medical imaging, Vaccine, Ophthalmology, Facebook, DecisionDx-UMSeq, DecisionDx-UM, DecisionDx-PRAME, Castle Biosciences, DECISIONDX-UMSEQ, DECISIONDX-UM, DECISIONDX-PRAME, CASTLE BIOSCIENCES

DecisionDx-UMSeq is Castles 7-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to uveal melanoma.

Key Points: 
  • DecisionDx-UMSeq is Castles 7-gene test that uses next-generation sequencing (NGS) to identify somatic mutations relevant to uveal melanoma.
  • DecisionDx-UM is the standard of care in the management of newly diagnosed UM in the majority of ocular oncology practices in the United States.
  • The study titled, Analytical validation and performance of a 7-gene next-generation sequencing panel in uveal melanoma, was recently published in the peer-reviewed journal Ocular Oncology and Pathology.
  • Elevated expression of PRAME has been associated with an increased risk of metastasis in patients with uveal melanoma.

Eisai Enters Into Exclusive Licensing Agreement with Roivant Concerning Investigational Anticancer Agent H3B-8800, a Splicing Modulator

Retrieved on: 
Thursday, January 6, 2022
Roivant Sciences, RNA transfection, Development, Biomedicine, Research, Patient, Cancer, Lymphatic system, Myelodysplastic syndrome, End-user license agreement, License, Data science, Splice, SF3B1, RNA, Sale, Sequencing, Genetic code, Intron, Nature Medicine, Pharmaceutical industry, Microdeletion syndrome, Eisai

H3B-8800 (Roivant's Development Code: RVT-2001) is a splicing modulator compound, discovered by Eisai's U.S. research subsidiary H3 Biomedicine Inc., which is undergoing development as an investigational anticancer agent.

Key Points: 
  • H3B-8800 (Roivant's Development Code: RVT-2001) is a splicing modulator compound, discovered by Eisai's U.S. research subsidiary H3 Biomedicine Inc., which is undergoing development as an investigational anticancer agent.
  • Mutations in splicing factor-encoding genes are observed in multiple hematological malignancies and solid tumors.
  • (1),(2) H3B-8800 binds to SF3B1, and demonstrated significant antitumor activity in preclinical models by modulating the disruption of mRNA splicing in cancer.
  • Eisai believes that this License Agreement with Roivant will lead to the maximization of the value of H3B-8800.

Roivant Licenses Splicing Modulator and Announces Upcoming Presentation at 40th Annual J.P. Morgan Healthcare Conference

Retrieved on: 
Wednesday, January 5, 2022
Clinical trial, Roivant Sciences, Transfusion-dependent anemia, Securities Act of 1933, Erythropoiesis, Iron overload, Myelodysplastic syndrome, Securities Exchange Act of 1934, Patient, Environment, JPM, U.S. Securities and Exchange Commission, Conference, Risk, SF3B1, Eisai, GLOBE, NEW, MDS, Cytopenia, Fatigue, End organ damage, Dizziness, Anemia, Pharmaceutical industry, Risk management

RVT-2001 is an orally available small molecule modulator of splicing factor 3B subunit 1 (SF3B1) with over 80 human subjects exposed to date.

Key Points: 
  • RVT-2001 is an orally available small molecule modulator of splicing factor 3B subunit 1 (SF3B1) with over 80 human subjects exposed to date.
  • Roivant plans to develop RVT-2001 as a first-in-class therapy for transfusion-dependent anemia in patients with lower-risk myelodysplastic syndromes (MDS).
  • Additional details on RVT-2001 and the companys development plan will be provided during Roivants presentation at the 40th Annual J.P. Morgan Healthcare Conference.
  • The presentation by Roivants chief executive officer, Matthew Gline, is scheduled for Monday, Jan. 10, 2021, at 2:15 p.m.

Prelude Therapeutics Announces Presentation of Encouraging Data from Multiple Programs at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics

Retrieved on: 
Thursday, October 7, 2021
Therapy, SDMA, Poster, Biotechnology, Central nervous system, Goal, GBM, Investigational New Drug, CDK9, Melanoma, IDH1, Cancer, AACR, CR, Company, Patient, SMARCA2, Lymphoma, MCL1, Conference, COVID-19, ACC, Glioblastoma, Phase 1, Mutation, U.S. Securities and Exchange Commission, MYC, Brain, AE, PRMT5, SD, Publication, Thrombocytopenia, Uveal melanoma, Private Securities Litigation Reform Act, Forward-looking statement, Lymphatic system, GLOBE, Adenoid cystic carcinoma, Apoptosis, Security (finance), SF3B1, DNA, Anemia, Pharmaceutical industry, Medical imaging

WILMINGTON, Del., Oct. 07, 2021 (GLOBE NEWSWIRE) -- Prelude Therapeutics Inc. (Nasdaq: PRLD), a clinical-stage precision oncology company, today announced the presentation of data from multiple pipeline programs, including the dose escalation portions of the Company’s ongoing Phase 1 trials of lead oral protein arginine methyltransferase 5 (PRMT5) inhibitors PRT543 and PRT811. These data will be featured at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10, 2021.

Key Points: 
  • These data will be featured at the AACR-NCI-EORTC Virtual International Conference on Molecular Targets and Cancer Therapeutics being held October 7-10, 2021.
  • We remain on track to submit an IND application and initiate a Phase 1 clinical trial by year-end.
  • A copy of each poster will be available in the Publications section of the Prelude Therapeutics website.
  • Prelude Therapeutics is a clinical-stage precision oncology company developing innovative drug candidates targeting critical cancer cell pathways.